Romualdo Barroso-Sousa

Dr. Romualdo Barroso-Sousa


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
WBWilliam T. Barry
William T. Barry
AGAna C. Garrido-Castro
Ana C. Garrido-Castro
FHF. Stephen Hodi
F. Stephen Hodi
LMLe Min
Le Min
STSara M. Tolaney
Sara M. Tolaney
The recognition that overexpression of immune checkpoint molecules in the tumor microenvironment plays a crucial role in antitumor immunity evasion has revolutionized cancer therapy.1-3 Currently, 6 immune checkpoint inhibitors (ICI) have been approved for the treatment of different advanced solid tumors: the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitor ipilimumab; 2 PD-1 (programmed cell death protein 1) inhibitors, nivolumab and pembrolizumab; and 3 PD-L1 (programmed cell death 1 ligand 1) inhibitors, atezolizumab, avelumab, and durvalumab. Additionally, combination therapy of ipilimumab plus nivolumab has been approved for treatment of advanced melanoma. Given the still-growing list of cancer types in which ICI have demonstrated clinical activity, their use is expected to increase in the coming years.4

5 May 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SPSachin Pai
Sachin Pai
BCBenedito A. Carneiro
Benedito A. Carneiro
JMJose Mauricio Mota
Jose Mauricio Mota
RCRicardo L. B. Costa
Ricardo L. B. Costa
CLCaio Abner Leite
Caio Abner Leite
FGFrancis Giles
Francis Giles
Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal. The Wnt pathway mediates biological processes by a canonical or noncanonical pathway, depending on the involvement of β-catenin in signal transduction. β-catenin is a core component of the cadherin protein complex, whose stabilization is essential for the activation of Wnt/β-catenin signaling. As multiple aberrations in this pathway occur in numerous cancers, WNT-directed therapy represents an area of significant developmental therapeutics focus. The recently described role of Wnt/β-catenin pathway in regulating immune cell infiltration of the tumor microenvironment renewed the interest, given its potential impact on responses to immunotherapy treatments. This article summarizes the role of Wnt/β-catenin pathway in cancer and ongoing therapeutic strategies involving this pathway.

5 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PCPaula Giselle Czaikoski
Paula Giselle Czaikoski
JMJosé Maurício Segundo Correia Mota
José Maurício Segundo Correia Mota
DNDaniele Carvalho Nascimento
Daniele Carvalho Nascimento
FSFabiane Sônego
Fabiane Sônego
FCFernanda Vargas e Silva Castanheira
Fernanda Vargas e Silva Castanheira
FCFernando Queiróz Cunha
Fernando Queiróz Cunha
Organ dysfunction is a major concern in sepsis pathophysiology and contributes to its high mortality rate. Neutrophil extracellular traps (NETs) have been implicated in endothelial damage and take part in the pathogenesis of organ dysfunction in several conditions. NETs also have an important role in counteracting invading microorganisms during infection. The aim of this study was to evaluate systemic NETs formation, their participation in host bacterial clearance and their contribution to organ dysfunction in sepsis. C57Bl/6 mice were subjected to endotoxic shock or a polymicrobial sepsis model induced by cecal ligation and puncture (CLP). The involvement of cf-DNA/NETs in the physiopathology of sepsis was evaluated through NETs degradation by rhDNase. This treatment was also associated with a broad-spectrum antibiotic treatment (ertapenem) in mice after CLP. CLP or endotoxin administration induced a significant increase in the serum concentrations of NETs. The increase in CLP-induced NETs was sustained over a period of 3 to 24 h after surgery in mice and was not inhibited by the antibiotic treatment. Systemic rhDNase treatment reduced serum NETs and increased the bacterial load in non-antibiotic-treated septic mice. rhDNase plus antibiotics attenuated sepsis-induced organ damage and improved the survival rate. The correlation between the presence of NETs in peripheral blood and organ dysfunction was evaluated in 31 septic patients. Higher cf-DNA concentrations were detected in septic patients in comparison with healthy controls, and levels were correlated with sepsis severity and organ dysfunction. In conclusion, cf-DNA/NETs are formed during sepsis and are associated with sepsis severity. In the experimental setting, the degradation of NETs by rhDNase attenuates organ damage only when combined with antibiotics, confirming that NETs take part in sepsis pathogenesis. Altogether, our results suggest that NETs are important for host bacterial control and are relevant actors in the pathogenesis of sepsis.

1 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LCLuís Felipe Campesato
Luís Felipe Campesato
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
LJLeandro Jimenez
Leandro Jimenez
BCBruna R. Correa
Bruna R. Correa
JSJorge Sabbaga
Jorge Sabbaga
ACAnamaria Camargo
Anamaria Camargo
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

4 February 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
TKTanya E. Keenan
Tanya E. Keenan
SPSonia Pernas
Sonia Pernas
PEPedro Exman
Pedro Exman
EJEsha Jain
Esha Jain
STSara M. Tolaney
Sara M. Tolaney
Purpose: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and PTEN alterations, defined as nonsynonymous mutations or 1 or 2 copy deletions, were associated with clinical benefit to anti-PD-1/L1 therapy in mTNBC. Experimental Design: We identified patients with mTNBC, who consented to targeted DNA sequencing and were treated with ICIs on clinical trials between April 2014 and January 2019 at Dana-Farber Cancer Institute (Boston, MA). Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were correlated with tumor genomic features. Results: Sixty-two women received anti-PD-1/L1 inhibitors alone (23%) or combined with targeted therapy (19%) or chemotherapy (58%). High TMB (18%) was associated with significantly longer PFS (12.5 vs. 3.7 months; P = 0.04), while PTEN alterations (29%) were associated with significantly lower ORR (6% vs. 48%; P = 0.01), shorter PFS (2.3 vs. 6.1 months; P = 0.01), and shorter OS (9.7 vs. 20.5 months; P = 0.02). Multivariate analyses confirmed that these associations were independent of performance status, prior lines of therapy, therapy regimen, and visceral metastases. The survival associations were additionally independent of PD-L1 in patients with known PD-L1 and were not found in mTNBC cohorts treated with chemotherapy (n = 90) and non-ICI regimens (n = 169). Conclusions: Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and PTEN alterations were associated with longer and shorter survival, respectively. These observations warrant validation in larger datasets.

25 April 2016 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
OMOtto Metzger-Filho
Otto Metzger-Filho
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.